Form 4: MindMed Director David Gryska Granted 75,187 Stock Options

Mind Medicine (MindMed) Inc. Director David W. Gryska was granted 75,187 stock options with an exercise price of $7.3 per share, vesting monthly over a year or earlier under specific conditions.

Summary

• David W. Gryska, a Director of Mind Medicine (MindMed) Inc. (MNMD), was granted 75,187 stock options.
• The transaction date for this grant was June 12, 2025.
• Each stock option has an exercise price of $7.3 per common share.
• The options have an expiration date of June 11, 2035.
• The stock options vest and become exercisable as to 1/12th of the underlying shares on each monthly anniversary of the grant date.
• Alternatively, if the Company's annual meeting immediately following the grant date takes place prior to the first anniversary, the options will vest immediately prior to that annual meeting.
• Vesting is subject to Mr. Gryska's continued service through the applicable vesting date.
• Following this reported transaction, Mr. Gryska beneficially owns 75,187 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns the director's incentives with shareholder value creation. It's a standard compensation practice and indicates commitment, though it doesn't represent immediate financial gain for the company.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance and stock price appreciation.
• Equity compensation is a common method to attract and retain experienced board members.

Negatives

• The grant itself does not provide immediate cash flow to the company.
• Future exercise of these options could lead to a minor dilutive effect on existing shares, although this is a standard aspect of equity compensation plans.

Risks

• The value of the stock options is contingent on Mind Medicine (MindMed) Inc.'s common share price exceeding the exercise price of $7.3 per share; if the stock price remains below this threshold, the options may not be in-the-money.
• Vesting of the options is subject to the reporting person's continued service, meaning the options could be forfeited if service ceases before vesting is complete.

Future Outlook

The grant of stock options provides a long-term incentive for the director, with vesting tied to future service and potential value creation linked to the company's stock performance over the next decade.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and pharmaceutical sectors, as a form of non-cash compensation designed to align the interests of board members with those of shareholders and to incentivize long-term growth and performance.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a standard practice within the biotechnology and pharmaceutical industries, aligning with global benchmarks for corporate governance and executive incentives.
• While the specific size of the grant (75,187 options) and the exercise price ($7.3) would require detailed comparison to compensation packages for directors at similarly sized or stage-appropriate companies within the biotech sector (e.g., companies with comparable market capitalization, R&D pipelines, or revenue stages), the mechanism itself is widely adopted.

Related Party Transactions

• The grant of stock options to David W. Gryska, a Director of Mind Medicine (MindMed) Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if the director's incentivized performance leads to stock price appreciation. There is also a potential for minor dilution if and when the options are exercised in the future.

Next Steps

• The stock options will vest monthly over the next year, or potentially earlier upon the company's annual meeting, contingent on the director's continued service.
• The director may choose to exercise these options at any point after vesting and before the expiration date of June 11, 2035, provided the stock price is favorable.

Key Dates

Keywords

Mind Medicine, MNMD, Stock Option, Director, David Gryska, SEC Form 4, Insider Transaction, Equity Compensation, Biotechnology, Pharmaceutical